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ABSTRACT
Introduction: Impaired renal function is a
major complication of type 2 diabetes mellitus
(T2DM). Mild renal impairment is present in
38% of patients with T2DM and may impact
choice of antihyperglycemic agent.
Sulfonylureas and dipeptidyl peptidase-4 (DPP-
4) inhibitors are commonly used to treat
hyperglycemia in patients with T2DM and
renal impairment. Although in general
sulfonylurea use is associated with an
increased risk of hypoglycemia and weight
gain, while DPP-4 inhibitor use is associated
with a low risk of hypoglycemia, and is weight
neutral, the relative efficacy and tolerability of
these agents in patients with mild renal
impairment has not been evaluated.
Methods: In a post hoc analysis, data from
1,211 subjects with T2DM and mild renal
impairment (estimated glomerular filtration
rates of 60 to \90 mL/min/1.73 m2), who
completed 25 or 30 weeks of one of three
double-blind clinical trials comparing the DPP-
4 inhibitor sitagliptin 100 mg/day with
sulfonylureas in titrated doses, were pooled.
The analysis compared change from baseline in
glycated hemoglobin (HbA1c), fasting plasma
glucose (FPG), body weight, incidence of
symptomatic hypoglycemia and the
percentages of subjects meeting a composite
endpoint of HbA1c decrease [0.5% without
symptomatic hypoglycemia or body weight
gain between sitagliptin and sulfonylurea
treatment groups.
Results: HbA1c and FPG decreased similarly with
sitagliptin or sulfonylurea. A lower incidence of
hypoglycemia was observed with sitagliptin.
Body weight decreased with sitagliptin but
increased with sulfonylurea. A greater
percentage of subjects treated with sitagliptin
(41.1%) than treated with sulfonylurea (16.9%)
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achieved the composite endpoint of [0.5%
HbA1c reduction with no symptomatic
hypoglycemia or body weight gain.
Conclusion: In this analysis of subjects with
T2DM and mild renal impairment, treatment
with sitagliptin provided glycemic efficacy
similar to sulfonylurea, with less hypoglycemia
and with body weight loss compared to body
weight gain seen with sulfonylurea.
Trial Registrations: ClinicalTrials.gov
#NCT00482079, #NCT00094770, #NCT00701090.
Keywords: DPP-4; Hypoglycemia; Incretins;
Renal impairment; Weight gain; Type 2
diabetes mellitus
INTRODUCTION
Among the many complications of type 2
diabetes mellitus (T2DM) arising from
prolonged hyperglycemia, as well as from
comorbid conditions such as hypertension, is
chronic kidney disease (CKD), which is present
in up to 40% of patients with T2DM [1].
Glycemic control reduces the incidence and
progression of microvascular complications of
diabetes [2, 3], but achieving adequate glycemic
control in patients with kidney disease can be
challenging. This challenge may be
underappreciated in patients with mild
impairment in kidney function, who account
for around 38% of patients with T2DM [4].
The routine reporting of estimated
glomerular filtration rate (eGFR) by clinical
laboratories, most commonly using the
Modification of Diet in Renal Disease (MDRD)
equation [5], allows clinicians a greater
awareness of patients’ level of renal function
and a greater recognition of even mild
impairment. The introduction of sodium
glucose co-transporter 2 inhibitors (SGLT2
inhibitors), a class of antihyperglycemic agent
with a renal-based mechanism of action, has
brought added emphasis to the importance of
renal function in choice of treatment for T2DM.
SGLT2 inhibitors demonstrate decreased
glycemic efficacy as renal function declines,
and this decrement begins in mild renal
impairment [6]. Mild renal impairment may be
relevant to metformin use as well: metformin is
recommended as first-line therapy in most
patients [7], but prescribing guidelines prohibit
its use at specific thresholds of serum creatinine
levels which correspond to only mild
reductions in eGFR in some patients [8].
In the Fourth National Health and Nutrition
Examination Survey (NHANES IV),
sulfonylureas were the most commonly used
antihyperglycemic agent in those with T2DM
and mild CKD, though this was before the
introduction of DPP4-inhibitors and other new
agents [1]. Sitagliptin is a DPP4-inhibitor which,
by preventing degradation of the incretins’
glucagon-like peptide-1(GLP-1) and gastric
inhibitory polypeptide (GIP), stimulates
insulin release in a glucose-dependent manner
[9]. Sitagliptin is approved for patients with all
stages of CKD [10]; as sitagliptin is subject
primarily to renal elimination [11], dose
adjustment is recommended in patients with
moderate-to-severe renal impairment or on
dialysis so as to maintain drug exposure
similar to that obtained in patients with
normal renal function or only mild renal
impairment [12]. A substantial number of large
clinical studies have demonstrated sitagliptin to
be generally safe and well tolerated [13]. In
particular, because of the glucose-dependent
nature of the insulinotropic effect of sitagliptin,
the risk of hypoglycemia associated with use of
this therapy is very low, except when used in
combination with an agent that induces
glucose-independent insulin secretion [14].
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The efficacy and safety of sitagliptin vs.
sulfonylurea in patients with T2DM and
moderate-to-severe CKD or end-stage renal
disease have been previously studied, showing
similar glycemic efficacy between the two
agents, and a lower risk of hypoglycemia and
less weight gain with sitagliptin treatment, but
otherwise generally similar safety and
tolerability [15, 16]. The current study is a post
hoc analysis of data pooled from 3 clinical trials,
comparing the efficacy, rates of hypoglycemia,
and changes in body weight in patients with
T2DM and mild renal impairment who were
randomized to either sitagliptin or a
sulfonylurea.
Subjects with mild renal impairment (eGFR
of C60 to\90 mL/min/1.73 m2) were identified
for this analysis using the MDRD equation to
estimate glomerular filtration rate (GFR) [17]. In
one of the 3 studies (referred to as Study 3), GFR
could be estimated by both the MDRD and the
Chronic Kidney Disease Epidemiology
Collaboration (CKD-epi) serum creatinine [18]
equations. The MDRD equation is imprecise
and systematically underestimates GFR at
higher levels of renal function [19]. Therefore,
to evaluate the accuracy of classification of
subject renal function by the MDRD equation
(the only method available for Studies 1 and 2),
baseline eGFR and renal function classification
were evaluated by both equations for all
subjects in Study 3 and compared.
METHODS
Data Sources
This was a post hoc analysis of pooled data from
subjects who participated in one of three
randomized, double-blind trials in which
sitagliptin was compared to a sulfonylurea,
had mild renal impairment (eGFR of C60 to
\90 mL/min/1.73 m2) at baseline as
determined by the 4-variable MDRD equation
[17] (meeting eGFR criteria for mild [Stage 2]
CKD [20]), had glycated hemoglobin (HbA1c)
data at the analysis time points, and had no
major protocol violations. There was no rescue
therapy in these trials, as subjects with
persistent hyperglycemia were discontinued.
In Study 1 (Sitagliptin Protocol 010,
ClinicalTrials.gov#NCT00482079) [21], 743
subjects were 21–76 years of age with baseline
HbA1c from 6.5 to \10.0% on diet alone; for
Study 2 (Sitagliptin Protocol 024,
ClinicalTrials.gov#NCT00094770) [22, 23],
1,172 subjects were 18–78 years of age with
baseline HbA1c from 6.5 to 10.0% on
background metformin monotherapy; and for
Study 3 (Sitagliptin Protocol 803;
ClinicalTrials.gov#NCT00701090) [24], 1,034
subjects were C18 years of age with baseline
HbA1c from 6.5 to 9.0% on background
metformin monotherapy.
In Study 1, a dose-range finding study,
subjects were randomized in an equal ratio
among six treatment groups, of which two are
appropriate for inclusion in the present
analyses: the group randomized to sitagliptin
(100 mg per day administered as 50 mg twice
daily) and the group randomized to glipizide (in
titrated doses). The primary study duration was
12 weeks, subsequently extended to 104 weeks.
In Study 2, subjects were randomized 1:1 to
sitagliptin (100 mg per day) or glipizide (in
titrated doses). Study duration was 104 weeks
with the primary time point at Week 52. In
Study 3, subjects were randomized 1:1 to
sitagliptin (100 mg per day) or glimepiride (in
titrated doses). Study duration was 30 weeks. In
all 3 studies, sulfonylureas (or matching
placebo) were titrated based on self-performed
fingerstick glucose values. Up-titration was
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withheld if the investigator considered that up-
titration would place the subject at
unacceptable risk for hypoglycemia, and
down-titration could be done at any time
during the study to prevent recurrent
hypoglycemic events. The mean ± standard
deviation dose of sulfonylurea achieved during
the analysis period in subjects included in this
analysis was 10.9 ± 5.9 mg glipizide per day,
10.4 ± 6.5 mg glipizide per day, and
2.0 ± 1.4 mg glimepiride per day in studies 1,
2, and 3, respectively.
As indicated above, the three studies had
slight differences in their protocols, including
background therapy (i.e., diet/exercise or
metformin) and specific sulfonylurea
comparator. However, efficacy and safety in
both backgrounds are relevant to this analysis.
Therefore, because it is not expected that a
stable metformin background would impact
body weight or hypoglycemic events, and
because similar efficacy and side effect profiles
of the two second-generation sulfonylureas
were expected, data were combined from the
three studies in order to increase the power and
generalizability of the analysis.
All studies contributing data to the analysis
reported here were conducted in accordance
with principles of Good Clinical Practice and
were approved by the appropriate institutional
review boards and regulatory agencies. The
analysis in this article is based on previously
conducted studies, and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Analysis Endpoints
Evaluation endpoints were changes from
baseline in HbA1c, fasting plasma glucose
(FPG), and body weight. The percentages of
subjects with HbA1c\7.0%, the percentages of
subjects with HbA1c decrease [0.5%, and the
percentages of subjects meeting a composite
endpoint of HbA1c decrease [0.5% with no
symptomatic hypoglycemia and no body
weight gain at the end of the study periods
were calculated. The percentages of subjects
reporting at least one adverse event (AE) of
symptomatic hypoglycemia, and the exposure-
adjusted event rate of reported AEs of
symptomatic hypoglycemia that occurred
during the analysis period were also
calculated. An AE of symptomatic
hypoglycemia was defined as any episode with
symptoms consistent with hypoglycemia; there
was no requirement for confirmation of
hypoglycemia by a measurement of blood
glucose levels. Severe hypoglycemia was
defined as an episode of hypoglycemia that
required assistance, either medical or non-
medical. Episodes with a markedly depressed
level of consciousness, a loss of consciousness,
or seizure were classified as having required
medical assistance, whether or not medical
assistance was obtained.
Statistical Analysis
In each study, the period evaluated began at
first dose of sitagliptin or sulfonylurea and
ended as close as possible to the final time
point for the study of shortest duration (Week
30 of Study 3).For Study 1, Week 25 data were
used for all endpoints. For Study 2, Week 30
data were used for HbA1c and FPG and Week 24
data for body weight. For Study 3, Week 30 data
were used for all endpoints. The incidence of
hypoglycemia was assessed through Week 25
(Study 1) or 30 (Studies 2 and 3). Since
treatment effects for both sitagliptin and
sulfonylurea generally plateau by 6 months,
these time points were considered to be
similar with regard to the endpoints of
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interest. Further, any minor effects related to
the 5 week difference would be equally
balanced between the two treatment groups.
Results at the time point used for this analysis,
for each individual study for the full per-
protocol analysis population, are provided in
supplementary Table 1.
To be included in the analysis population,
subjects with appropriate eGFR at baseline had
to have completed Study 1 through Week 25 or
Studies 2 or 3 through Week 30, have a baseline
and end of analysis period HbA1c measurement,
and have no major protocol violations.
Analysis of covariance was used to compare
the treatment group changes from baseline for
the continuous endpoints, at time points
indicated. The model controlled for treatment,
study, and baseline value. The difference
between treatment groups in change from
baseline was assessed by testing the difference
in the least squares mean change from baseline.
Percentages and event rates were assessed using
the method of Miettinen & Nurminen [25],
stratified by study to calculate a nominal P value
for between-group differences. The event rate
was calculated as number of events divided by
total subject-years of exposure. The total
subject-years of exposure were calculated as
the sum, over all subjects, of the time from
the first dose to last dose of study medication
for the time period included in this analysis.
Using all available data from Study 3,
baseline eGFR and mild renal impairment
classification using the 4-variable MDRD
equation was compared with the baseline
values and classification obtained using the
CKD-epi creatinine equation, considering
CKD-epi eGFR to be the reference value. All
analyses were done using SAS (developed by SAS
Institute Inc., Cary, NC, USA.), version 9.3.
RESULTS
Of the 1,538 randomized subjects with mild
renal impairment across the three studies
(N = 774 treated with sitagliptin and N = 764
treated with a sulfonylurea), 1,211 (78.7%) met
the criteria for inclusion in this analysis
[N = 601 (77.6%) treated with sitagliptin and
N = 610 (79.8%) treated with a sulfonylurea].
Baseline demographic and anthropometric
characteristics of subjects in the two groups of
the pooled study cohort were similar (Table 1).
Table 1 Baseline demographic and anthropometric






Age (years) 57.7 ± 8.5 57.6 ± 9.4
Male gender [n (%)] 326 (54.2) 357 (58.5)
Race [n (%)]
White 428 (71.2) 416 (68.2)
Asian 56 (9.3) 80 (13.1)
Black 18 (3.0) 21 (3.4)
Other 99 (16.5) 93 (15.2)
Body weight (kg) 85.8 ± 16.6 86.4 ± 16.8














FPG (mg/dL) 154.9 ± 35.9 156.9 ± 40.1
Duration of T2DM (years) 6.4 ± 4.9 5.8 ± 4.5
Data are expressed as mean ± standard deviation or
frequency [n (%)]
GFR glomerular ﬁltration rate, FPG fasting plasma glucose,
T2DM type 2 diabetes mellitus. To convert FPG in mg/dL
to mmol/L divide by 18
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The mean age of subjects in the cohort was
57.7 years and their mean eGFR was 75.9 mL/
min/1.73 m2. The mean duration of T2DM in
the cohort was 6.1 years.
Changes from baseline in HbA1c were similar
between the sitagliptin- and the sulfonylurea-
treated groups (sitagliptin = -0.62%,
sulfonylurea = -0.68%; sitagliptin difference
from sulfonylurea group 0.06%, P = 0.104;
Fig. 1). The percentages of subjects with
HbA1c\7.0% or with [0.5% reduction in
HbA1c were also similar between the two
groups (differences from sulfonylurea group
-4.7%, P = 0.092, Fig. 2 and 0.2%, P = 0.956,
Fig. 3, respectively). The FPG changes from
baseline observed with sitagliptin treatment
and with sulfonylurea treatment at Weeks 25
or 30 (Fig. 4) were similar (difference from
sulfonylurea group 1.6 mg/dL, P = 0.298).
A significantly smaller percentage of subjects
with mild renal impairment treated with
sitagliptin reported experiencing at least one
episode of symptomatic hypoglycemia
compared with subjects treated with a
sulfonylurea (6.5% with sitagliptin vs. 25.9%
with SU; P\0.001; Fig. 5). In addition, the
reported number of symptomatic
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Fig. 1 Glycated hemoglobin (HbA1c) change from base-
line after 25–30 weeks of treatment with sitagliptin or a





















Sitagliptin (N = 601) 






Fig. 2 Percentage of subjects with glycated hemoglobin
(HbA1c)\7.0% after 25–30 weeks of treatment with


































Sitagliptin (n = 592)




Fig. 4 Fasting plasma glucose (FPG) change from baseline
after 25–30 weeks of treatment with sitagliptin or a


























100 Sitagliptin (n = 601) 






Fig. 3 Percentage of subjects with [0.5% reduction in
glycated hemoglobin (HbA1c) after 25–30 weeks of treat-
ment with either sitagliptin or a sulfonylurea
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during the analysis period (79) was lower
compared to the sulfonylurea group (609),
which, due to the similarity in treatment
durations, led to a significantly lower event
rate for symptomatic hypoglycemia in the
sitagliptin group compared with the
sulfonylurea group (Fig. 6). One subject in this
cohort, treated with a sulfonylurea, reported at
least one episode of severe hypoglycemia, while
no subject treated with sitagliptin reported an
event of severe hypoglycemia.
Mean body weight in the sulfonylurea group
increased while that in the sitagliptin group
decreased (Fig. 7), yielding a significant
between-group difference of -2.3 kilograms
(P\0.001).
In the sitagliptin group, 41.1% of subjects
achieved the composite endpoint of an HbA1c
decrease of [0.5% with no reported event of
symptomatic hypoglycemia and no increase in
body weight, a substantially larger percentage
than in the sulfonylurea group (between-group
difference 24.6%, P\0.001; Fig. 8).
In Study 3, kidney function was evaluated by
both the standard MDRD equation and the
more recently validated CKD-epi equation. A
comparison of the results obtained by each





































40 Sitagliptin (N = 601) 






Fig. 5 Percentage of subjects with at least one episode of
symptomatic hypoglycemia during treatment with sitag-






250 Sitagliptin (n = 601) 






































Fig. 6 Event rate of symptomatic hypoglycemia during


































Sitagliptin (N = 596) 




Fig. 7 Body weight (BW) change from baseline after
25–30 weeks of treatment with either sitagliptin or a



























60 Sitagliptin (n = 596)






Fig. 8 Percentage of subjects meeting the composite
endpoint of glycated hemoglobin (HbA1c) decrease
[0.5% with no symptomatic hypoglycemia and no body
weight gain after 25–30 weeks of treatment with either
sitagliptin or a sulfonylurea
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was used to classify subjects for the current
pooled analysis, approximately 6.1% of subjects
in the pooled analysis would not have met
criteria for mild renal impairment (Table 2). Of
521 subjects classified by MDRD as having eGFR
of 60 to \90 mL/min/1.73 m2, 3 were classified
by CKD-epi as having eGFR\60 mL/min/
1.73 m2 and 29 were classified by CKD-epi as
having eGFR C 90 mL/min/1.73 m2.
DISCUSSION
Tight glycemic control has been shown to
reduce the risk of incident renal disease and to
slow progression in patients with established
renal disease [2, 3]. However, the rates of
optimal glycemic control may be lower in
patients with mild renal impairment compared
to patients without renal disease or with more
advanced disease. For example, in NHANES IV
and in a large cohort of individuals at high risk
for kidney disease, those individuals with T2DM
who had mild CKD had significantly worse
glycemic control compared to those who had
no CKD or who had moderate or severe CKD [1,
26, 27]. The reasons for these findings are
unclear, but may be due to lower levels of
medical engagement by patients with mild
renal impairment compared to those with
more advanced renal impairment, or lower
levels of vigilance by physicians when patients
have only mild disease. This may be exacerbated
by the practice of laboratories reporting MDRD-
derived eGFR calculations as ‘‘C60’’ for all
individuals above that threshold, thus
providing a sense of reassurance that may not
be entirely warranted in patients with mild
renal impairment.
While the choice of antihyperglycemic
therapies for T2DM should take renal
functional status into account, clinicians may
not recognize mild renal impairment as a
category requiring such consideration. Several
clinical practice guidelines have recommended
the use of the CKD-epi equation for estimating
GFR, as the MDRD equation tends to
underestimate the true GFR in those with
higher GFR (e.g., mild renal impairment and
normal renal function) [28, 29]. However, in
routine clinical practice, the majority of clinical
laboratories continue to provide estimated GFR
values using the MDRD equation [5, 28].
In this post hoc analysis of subjects with
mild renal impairment, treatment with
sitagliptin or sulfonylureas provided similar
improvements in glycemic efficacy while there
was a significantly higher incidence of AEs of
symptomatic hypoglycemia with sulfonylurea
compared with sitagliptin. Sulfonylurea
treatment was also associated with weight gain
compared with weight loss with sitagliptin. The
results of this analysis show relative efficacy and
Table 2 The glomerular ﬁltration rates of all subjects in Study 3 were estimated using both the 4-variable Modiﬁcation of
Diet in Renal Disease (MDRD) equation and the Chronic Kidney Disease epidemiology collaboration (CKD-epi)
creatinine equation
Subject eGFR classiﬁcation <60 by MDRD ‡60 to <90 by MDRD >90 by MDRD Total
\60 by CKD-epi 49 (4.7) 3 (0.3) 0 (0.0) 52 (5.0)
60 to B89 by CKD-epi 6 (0.6) 489 (47.2) 16 (1.5) 511 (49.4)
[89 by CKD-epi 0 (0.0) 29 (2.8) 443 (42.8) 472 (45.6)
Total 55 (5.3) 521 (50.3) 459 (44.3) 1,035 (100.0)
A comparison of the results of subject classiﬁcation [n (%)] based on the results of each method is displayed
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tolerability in subjects with mild renal
impairment identified by MDRD eGFR that is
comparable to that obtained in the overall
population from which these subjects were
selected [21–24]. The overall findings of the
analysis reported herein are attributable to the
differing mechanisms of action of the two
classes of drugs evaluated. Sulfonylureas are
potent, glucose-independent insulin
secretagogues which act directly on pancreatic
beta cells [30]. Sulfonylureas stimulate a release
of insulin in a glucose-independent fashion,
making them effective antihyperglycemic
agents and also increasing the likelihood of
hypoglycemia. In contrast, the dipeptidyl
peptidase-4 (DPP-4) inhibitor sitagliptin acts
by stabilizing the DPP-4 substrates, GLP-1 and
GIP, both incretin hormones which act in a
glucose-dependent manner to increase the
secretion of insulin by beta cells [9].
DPP-4 inhibitors are generally considered to
be weight neutral, although the mild weight
loss observed in several studies of broad
populations of patients with T2DM [22–24],
and in this analysis, may be related to
stabilization of GLP-1; activation of the GLP-1
receptor with the GLP-1 agonist liraglutide has
been shown to decrease body weight in patients
with T2DM [31]. In contrast, weight gain with
sulfonylureas is a known potential side effect
which may result from increased insulin levels
[32].
One limitation of this analysis is that AEs of
hypoglycemia were reported based on
symptoms and did not require measurement
of blood glucose level. Another potential
limitation is the use of the MDRD eGFR
equation to identify the population with mild
renal impairment for this analysis, as this
equation has been shown to be less accurate
at higher levels of renal function compared to
the CKD-epi serum creatinine equation [18].
However, the comparison performed using data
from all subjects in Study 3, in which both
equations could be used, showed that the rate
of possible misclassification was low, with
approximately 94% of patients being
accurately categorized using the MDRD
equation. Moreover, as many clinical
laboratories continue to use the MDRD
equation to calculate eGFR whenever serum
creatinine is performed [5, 28], the analysis
reported here is relevant in real-world clinical
practice settings.
Patients with diabetes and comorbid mild
CKD represent a population at increased risk for
progression to end-stage renal disease and for
cardiovascular events compared to patients
with diabetes without renal disease [33].
Management of hyperglycemia with
minimization of side effects such as
hypoglycemia and weight gain is clinically
desirable in all patients with diabetes, but may
be particularly important in patients with
diabetes and CKD, including mild CKD, given
the greater risks associated with this
combination of diseases. From the current
analysis, one can conclude that in patients
with T2DM and mild renal impairment
sitagliptin produces glycemic control similar to
sulfonylureas but with substantially less
hypoglycemia and without the weight gain
generally observed with sulfonylureas.
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